Liquidia (LQDA) Scheduled to Post Quarterly Earnings on Wednesday

Liquidia (NASDAQ:LQDA) will be announcing its earnings results before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Liquidia Trading Down 2.7 %

NASDAQ LQDA opened at $10.73 on Tuesday. Liquidia has a 12-month low of $6.10 and a 12-month high of $16.99. The company has a fifty day simple moving average of $10.40 and a two-hundred day simple moving average of $11.55. The stock has a market cap of $823.96 million, a P/E ratio of -6.83 and a beta of 0.21.

Insiders Place Their Bets

In other news, Director Caligan Partners Lp bought 150,000 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was purchased at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the acquisition, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Michael Kaseta sold 3,892 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the completion of the transaction, the chief financial officer now owns 311,076 shares of the company’s stock, valued at approximately $3,456,054.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Caligan Partners Lp acquired 150,000 shares of the company’s stock in a transaction on Friday, August 30th. The stock was acquired at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the acquisition, the director now owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 21,551 shares of company stock worth $236,021. Corporate insiders own 30.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on LQDA shares. Bank of America reduced their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. HC Wainwright decreased their target price on Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. BTIG Research dropped their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Lifesci Capital started coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target for the company. Finally, Scotiabank assumed coverage on shares of Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).